Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
ArriVent BioPharma, Inc.
13D/A
Amendment 2
AVBP · 04272N102
|
5.8% |
10/8/2026
Event 10/6/2026
|
|||
| Orbimed Advisors LLC | 5.8% | ||||
| OrbiMed Capital GP VIII LLC | 2.9% | ||||
| OrbiMed Asia GP IV, L.P. | 2.9% | ||||
| OrbiMed Advisors IV Limited | 2.9% | ||||
|
ADARx Pharmaceuticals, Inc.
13D
00654F105
|
14.0% |
10/2/2026
Event 9/28/2026
|
|||
| Orbimed Advisors LLC | 14.0% | ||||
| Orbimed Capital GP VII LLC | 13.4% | ||||
| Orbimed Advisors Israel II Ltd | 8.7% | ||||
| Orbimed Israel GP II, L.P. | 8.7% | ||||
| OrbiMed Genesis GP LLC | 0.6% | ||||
|
Electra Therapeutics, Inc.
13D
284825106
|
11.0% |
9/25/2026
Event 9/21/2026
|
|||
| Orbimed Advisors LLC | 11.0% | ||||
| Orbimed Capital GP VII LLC | 8.2% | ||||
| OrbiMed Genesis GP LLC | 2.8% | ||||
|
Braveheart Bio, Inc.
13D/A
Amendment 1
BRVE · 10567X101
|
13.5% |
9/10/2026
Event 9/8/2026
|
|||
| Orbimed Advisors LLC | 13.5% | ||||
| OrbiMed Capital GP IX LLC | 13.2% | ||||
| OrbiMed Genesis GP LLC | 0.3% | ||||
|
Braveheart Bio, Inc.
13D
BRVE · 10567X101
|
17.2% |
8/18/2026
Event 8/7/2026
|
|||
| Orbimed Advisors LLC | 17.2% | ||||
| OrbiMed Capital GP IX LLC | 16.9% | ||||
| OrbiMed Genesis GP LLC | 0.4% | ||||
|
BlossomHill Therapeutics, Inc.
13D
BLSM · 095130100
|
8.9% |
8/18/2026
Event 8/10/2026
|
|||
| Orbimed Advisors LLC | 8.9% | ||||
| OrbiMed Capital GP VIII LLC | 8.9% | ||||
|
Whitehawk Therapeutics, Inc.
13G/A
Amendment 1
WHWK · 00032Q104
|
7.3% |
8/14/2026
Event 6/30/2026
|
|||
| OrbiMed Advisors LLC | 7.3% | ||||
| OrbiMed Genesis GP LLC | 7.3% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 2
VTGN · 92840H400
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Orbimed Advisors LLC | 0% | ||||
| Orbimed Capital LLC | 0% | ||||
|
Spruce Biosciences, Inc.
13G
SPRB · 85209E208
|
4.8% |
8/14/2026
Event 6/30/2026
|
|||
| OrbiMed Advisors LLC | 4.8% | ||||
| OrbiMed Capital LLC | 2.5% | ||||
|
NeuroPace, Inc.
13G/A
Amendment 8
NPCE · 641288105
|
4.4% |
8/14/2026
Event 6/30/2026
|
|||
| OrbiMed Advisors LLC | 4.4% | ||||
| OrbiMed Capital GP VI LLC | 4.4% | ||||
|
Lexeo Therapeutics, Inc.
13G
LXEO · 52886X107
|
4.1% |
8/14/2026
Event 6/30/2026
|
|||
| OrbiMed Advisors LLC | 4.1% | ||||
| OrbiMed Capital LLC | 1.0% | ||||
|
Immunic, Inc.
13G
IMUX · 4525EP101
|
5.3% |
8/14/2026
Event 6/30/2026
|
|||
| OrbiMed Advisors LLC | 5.3% | ||||
| OrbiMed Genesis GP LLC | 5.3% | ||||
| OrbiMed Capital LLC | 2.8% | ||||
|
Forte Biosciences, Inc.
13G/A
Amendment 2
FBRX · 34962G208
|
6.2% |
8/14/2026
Event 6/30/2026
|
|||
| Orbimed Advisors LLC | 6.2% | ||||
| OrbiMed Capital GP IX LLC | 5.1% | ||||
| Orbimed Capital LLC | 1.5% | ||||
|
MBX Biosciences, Inc.
13D/A
Amendment 3
MBX · 55287L101
|
6.4% |
8/10/2026
Event 8/6/2026
|
|||
| Orbimed Advisors LLC | 6.4% | ||||
| Orbimed Capital GP VII LLC | 5.2% | ||||
| Orbimed Genesis GP LLC | 1.2% | ||||
|
Yarrow Bioscience, Inc.
13D
YARW · 92941V407
|
10.0% |
8/5/2026
Event 7/27/2026
|
|||
| Orbimed Advisors LLC | 10.0% | ||||
| OrbiMed Capital GP X LLC | 8.7% | ||||
| OrbiMed Capital GP X, LP | 8.7% | ||||
| OrbiMed Genesis GP LLC | 1.3% | ||||
|
Scribe Therapeutics, Inc.
13D
SCTX · 811033109
|
7.2% |
7/29/2026
Event 7/27/2026
|
|||
| Orbimed Advisors LLC | 7.2% | ||||
| Orbimed Capital GP VIII LLC | 7.2% | ||||
|
Q32 Bio Inc.
13D/A
Amendment 4
QTTB · 746964105
|
13.9% |
7/20/2026
Event 7/16/2026
|
|||
| Orbimed Advisors LLC | 13.9% | ||||
| Orbimed Capital GP VII LLC | 11.8% | ||||
| OrbiMed Genesis GP LLC | 2.1% | ||||
|
Enliven Therapeutics, Inc.
13D/A
Amendment 5
ELVN · 29337E102
|
9.5% |
6/24/2026
Event 6/22/2026
|
|||
| Orbimed Advisors LLC | 9.5% | ||||
| Orbimed Capital GP VII LLC | 9.2% | ||||
| Orbimed Genesis GP LLC | 0.3% | ||||
| Orbimed Capital LLC | 0% | ||||
|
Enliven Therapeutics, Inc.
13D/A
Amendment 4
ELVN · 29337E102
|
10.9% |
6/17/2026
Event 6/15/2026
|
|||
| Orbimed Advisors LLC | 10.9% | ||||
| Orbimed Capital GP VII LLC | 10.6% | ||||
| Orbimed Genesis GP LLC | 0.4% | ||||
| Orbimed Capital LLC | <0.1% | ||||
|
Shattuck Labs, Inc.
13D/A
Amendment 1
STTK · 82024L103
|
10.0% |
6/15/2026
Event 6/11/2026
|
|||
| Orbimed Advisors LLC | 10.0% | ||||
| OrbiMed Capital GP IX LLC | 8.3% | ||||
| OrbiMed Genesis GP LLC | 1.7% | ||||
|
Q32 Bio Inc.
13D/A
Amendment 3
QTTB · 746964105
|
17.4% |
6/1/2026
Event 5/28/2026
|
|||
| Orbimed Advisors LLC | 17.4% | ||||
| Orbimed Capital GP VII LLC | 14.8% | ||||
| OrbiMed Genesis GP LLC | 2.6% | ||||
|
Xilio Therapeutics, Inc.
13G
28422T209
|
10.0% |
5/15/2026
Event 3/31/2026
|
|||
| Orbimed Advisors LLC | 10.0% | ||||
| OrbiMed Capital GP X LLC | 7.5% | ||||
|
RAPT Therapeutics, Inc.
13G/A
Amendment 2
RAPT · 75382E109
|
0% |
5/15/2026
Event 3/31/2026
|
|||
|
NeuroPace Inc
13G/A
Amendment 7
NPCE · 641288105
|
6.2% |
5/15/2026
Event 3/31/2026
|
|||
| OrbiMed Advisors LLC | 6.2% | ||||
| OrbiMed Capital GP VI LLC | 6.2% | ||||
|
Forte Biosciences, Inc.
13G/A
Amendment 1
FBRX · 34962G208
|
4.3% |
5/15/2026
Event 3/31/2026
|
|||
| Orbimed Advisors LLC | 4.3% | ||||
| Orbimed Capital LLC | 1.5% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 3
AVTX · 05338F306
|
2.1% |
5/15/2026
Event 3/31/2026
|
|||
|
Q32 Bio Inc.
13D/A
Amendment 2
QTTB · 746964105
|
13.3% |
5/6/2026
Event 5/5/2026
|
|||
| Orbimed Advisors LLC | 13.3% | ||||
| Orbimed Capital GP VII LLC | 13.3% | ||||
|
Traws Pharma, Inc.
13D/A
Amendment 3
TRAW · 68232V884
|
11.9% |
5/5/2026
Event 4/16/2026
|
|||
| Orbimed Advisors LLC | 11.9% | ||||
| OrbiMed Capital GP VIII LLC | 11.9% | ||||
|
ImageneBio, Inc.
13D/A
Amendment 6
IKNA · 45175G108
|
13.1% |
4/29/2026
Event 4/14/2026
|
|||
| Orbimed Advisors LLC | 13.1% | ||||
| Orbimed Capital GP VI LLC | 9.6% | ||||
| OrbiMed Genesis GP LLC | 3.6% | ||||
| Orbimed Capital LLC | 1.2% | ||||
|
Prelude Therapeutics Inc
13D/A
Amendment 3
PRLD · 74065P101
|
16.0% |
4/23/2026
Event 4/21/2026
|
|||
| Orbimed Advisors LLC | 16.0% | ||||
| Orbimed Capital GP VI LLC | 14.6% | ||||
| OrbiMed Genesis GP LLC | 1.4% | ||||
| Orbimed Capital LLC | 1.0% | ||||
|
Sionna Therapeutics, Inc.
13D/A
Amendment 1
SION · 829401108
|
6.6% |
4/20/2026
Event 4/15/2026
|
|||
| Orbimed Advisors LLC | 6.6% | ||||
| OrbiMed Capital GP VIII LLC | 6.6% | ||||
|
Adicet Bio, Inc.
13D/A
Amendment 9
ACET · 007002108
|
8.8% |
4/10/2026
Event 4/8/2026
|
|||
| Orbimed Advisors LLC | 8.8% | ||||
| Orbimed Capital GP VI LLC | 2.9% | ||||
| Orbimed Capital GP V LLC | 5.9% | ||||
| OrbiMed Genesis GP LLC | 0% | ||||
| Orbimed Advisors Israel II Ltd | 0% | ||||
| Orbimed Israel GP II, L.P. | 0% | ||||
| Orbimed Israel GP Ltd. | 0% | ||||
| Orbimed Israel Biofund GP Limited Partnership | 0% | ||||
|
Q32 Bio Inc.
13D/A
Amendment 1
QTTB · 746964105
|
15.4% |
3/12/2026
Event 2/18/2026
|
|||
| Orbimed Advisors LLC | 15.4% | ||||
| Orbimed Capital GP VII LLC | 15.4% | ||||
|
PMV Pharmaceuticals, Inc.
13D/A
Amendment 4
PMVP · 69353Y103
|
0% |
3/4/2026
Event 3/2/2026
|
|||
| Orbimed Advisors LLC | 0% | ||||
| Orbimed Capital GP V LLC | 0% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 1
VTGN · 92840H400
|
4.2% |
2/17/2026
Event 12/31/2025
|
|||
| Orbimed Advisors LLC | 3.6% | ||||
| Orbimed Capital LLC | 4.2% | ||||
|
InspireMD, Inc.
13G
NSPR · 45779A846
|
7.4% |
2/17/2026
Event 12/31/2025
|
|||
| Orbimed Advisors LLC | 7.4% | ||||
| OrbiMed Capital GP IX LLC | 6.8% | ||||
|
CytomX Therapeutics, Inc.
13G/A
Amendment 1
CTMX · 23284F105
|
2.1% |
2/17/2026
Event 12/31/2025
|
|||
|
Cybin Inc.
13G
CYBN · 23256X100
|
4.9% |
2/17/2026
Event 12/31/2025
|
|||
| Orbimed Advisors LLC | 2.8% | ||||
| Orbimed Capital LLC | 4.9% | ||||
|
C4 Therapeutics, Inc.
13G/A
Amendment 3
CCCC · 12529R107
|
1.0% |
2/17/2026
Event 12/31/2025
|
|||
| OrbiMed Advisors LLC | 0.5% | ||||
| OrbiMed Capital LLC | 1.0% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 2
AVTX · 05338F306
|
6.4% |
2/17/2026
Event 12/31/2025
|
|||
|
ADC Therapeutics SA
13G/A
Amendment 1
ADCT · H0036K147
|
2.6% |
2/17/2026
Event 12/31/2025
|
|||
| Orbimed Advisors LLC | 2.1% | ||||
| Orbimed Capital LLC | 2.6% | ||||
|
MBX Biosciences, Inc.
13D/A
Amendment 2
MBX · 55287L101
|
7.7% |
2/11/2026
Event 2/5/2026
|
|||
| Orbimed Advisors LLC | 7.7% | ||||
| Orbimed Capital GP VII LLC | 6.3% | ||||
| OrbiMed Genesis GP LLC | 1.4% | ||||
|
Corvus Pharmaceuticals, Inc.
13D/A
Amendment 12
CRVS · 221015100
|
10.3% |
1/27/2026
Event 1/23/2026
|
|||
| Orbimed Advisors LLC | 10.3% | ||||
| Orbimed Capital GP V LLC | 10.3% | ||||
|
RAPT Therapeutics, Inc.
13G/A
Amendment 1
RAPT · 75382E109
|
6.6% |
11/14/2025
Event 9/30/2025
|
|||
|
InspireMD, Inc.
13G/A
Amendment 3
NSPR · 45779A846
|
4.1% |
11/14/2025
Event 9/30/2025
|
|||
|
C4 Therapeutics, Inc.
13G/A
Amendment 2
CCCC · 12529R107
|
5.0% |
11/14/2025
Event 9/30/2025
|
|||
| OrbiMed Advisors LLC | 2.3% | ||||
| OrbiMed Capital LLC | 5.0% | ||||
|
Vistagen Therapeutics, Inc.
13G
VTGN · 92840H400
|
5.3% |
11/14/2025
Event 9/30/2025
|
|||
| Orbimed Advisors LLC | 4.6% | ||||
| Orbimed Capital LLC | 5.3% | ||||
|
Terns Pharmaceuticals, Inc.
13D/A
Amendment 6
TERN · 880881107
|
4.8% |
11/5/2025
Event 11/3/2025
|
|||
| Orbimed Advisors LLC | 4.8% | ||||
| Orbimed Capital GP VII LLC | 3.1% | ||||
| OrbiMed Asia GP III, L.P. | 1.2% | ||||
| OrbiMed Advisors III Ltd | 1.2% | ||||
| OrbiMed Genesis GP LLC | 0.5% | ||||
|
PMV Pharmaceuticals, Inc.
13D/A
Amendment 3
PMVP · 69353Y103
|
9.4% |
10/27/2025
Event 10/23/2025
|
|||
| Orbimed Advisors LLC | 9.4% | ||||
| Orbimed Capital GP V LLC | 9.4% | ||||
|
Adicet Bio, Inc.
13D/A
Amendment 8
ACET · 007002108
|
9.6% |
10/10/2025
Event 10/8/2025
|
|||
| Orbimed Advisors LLC | 9.6% | ||||
| Orbimed Capital GP VI LLC | 2.9% | ||||
| Orbimed Capital GP V LLC | 5.9% | ||||
| OrbiMed Genesis GP LLC | 0.8% | ||||
| Orbimed Advisors Israel II Ltd | 0.4% | ||||
| Orbimed Israel GP II, L.P. | 0.4% | ||||
| Orbimed Israel GP Ltd. | 0.7% | ||||
| Orbimed Israel Biofund GP Limited Partnership | 0.7% | ||||
|
MBX Biosciences, Inc.
13D/A
Amendment 1
MBX · 55287L101
|
9.0% |
9/30/2025
Event 9/26/2025
|
|||
| Orbimed Advisors LLC | 9.0% | ||||
| Orbimed Capital GP VII LLC | 7.3% | ||||
| OrbiMed Genesis GP LLC | 1.7% | ||||
|
Shattuck Labs, Inc.
13D
STTK · 82024L103
|
10.0% |
9/2/2025
Event 8/25/2025
|
|||
| Orbimed Advisors LLC | 10.0% | ||||
| OrbiMed Capital GP IX LLC | 8.3% | ||||
| OrbiMed Genesis GP LLC | 1.7% | ||||
|
Compass Therapeutics, Inc.
13D/A
Amendment 6
CMPX · 20454B104
|
8.9% |
8/15/2025
Event 8/13/2025
|
|||
| Orbimed Advisors LLC | 8.9% | ||||
| Orbimed Capital GP V LLC | 8.9% | ||||
|
CytomX Therapeutics, Inc.
13G
CTMX · 23284F105
|
5.4% |
8/14/2025
Event 6/30/2025
|
|||
|
NeuroPace Inc
13G/A
Amendment 6
NPCE · 641288105
|
8.0% |
8/14/2025
Event 6/30/2025
|
|||
| OrbiMed Advisors LLC | 8.0% | ||||
| OrbiMed Capital GP VI LLC | 8.0% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 1
AVTX · 05338F306
|
8.9% |
8/14/2025
Event 6/30/2025
|
|||
| OrbiMed Advisors LLC | 8.9% | ||||
| OrbiMed Capital GP IX LLC | 6.0% | ||||
|
Verastem, Inc.
13G/A
Amendment 4
VSTM · 92337C203
|
2.4% |
8/14/2025
Event 6/30/2025
|
|||
|
X4 Pharmaceuticals, Inc
13G/A
Amendment 5
XFOR · 98420X103
|
1.7% |
8/14/2025
Event 6/30/2025
|
|||
|
ArriVent BioPharma, Inc.
13D/A
Amendment 1
AVBP · 04272N102
|
7.5% |
8/13/2025
Event 8/11/2025
|
|||
| Orbimed Advisors LLC | 7.5% | ||||
| OrbiMed Capital GP VIII LLC | 3.7% | ||||
| OrbiMed Asia GP IV, L.P. | 3.7% | ||||
| OrbiMed Advisors IV Limited | 3.7% | ||||
|
ImageneBio, Inc.
13D/A
Amendment 5
IKNA · 45175G108
|
6.9% |
7/30/2025
Event 7/25/2025
|
|||
| Orbimed Advisors LLC | 6.9% | ||||
| Orbimed Capital GP VI LLC | 6.7% | ||||
| OrbiMed Genesis GP LLC | 0.2% | ||||
| Orbimed Capital LLC | 1.2% | ||||
|
Passage BIO, Inc.
13D/A
Amendment 9
PASG · 702712100
|
4.3% |
7/24/2025
Event 7/22/2025
|
|||
| Orbimed Advisors LLC | 4.3% | ||||
| Orbimed Capital GP VII LLC | 4.3% | ||||
|
Passage BIO, Inc.
13D/A
Amendment 8
PASG · 702712100
|
7.8% |
7/21/2025
Event 7/17/2025
|
|||
| Orbimed Advisors LLC | 7.8% | ||||
| Orbimed Capital GP VII LLC | 7.8% | ||||
|
Passage BIO, Inc.
13D/A
Amendment 7
PASG · 702712100
|
9.5% |
7/9/2025
Event 7/7/2025
|
|||
| Orbimed Advisors LLC | 9.5% | ||||
| Orbimed Capital GP VII LLC | 9.5% | ||||
|
Ikena Oncology, Inc.
13D/A
Amendment 4
IKNA · 45175G108
|
16.7% |
6/18/2025
Event 6/14/2025
|
|||
| Orbimed Advisors LLC | 16.7% | ||||
| Orbimed Capital GP VI LLC | 16.2% | ||||
| OrbiMed Genesis GP LLC | 0.5% | ||||
| Orbimed Capital LLC | 3.3% | ||||
|
Enliven Therapeutics, Inc.
13D/A
Amendment 3
ELVN · 29337E102
|
13.4% |
6/17/2025
Event 6/16/2025
|
|||
| Orbimed Advisors LLC | 13.4% | ||||
| Orbimed Capital GP VII LLC | 13.0% | ||||
| Orbimed Genesis GP LLC | 0.4% | ||||
| Orbimed Capital LLC | 0.1% | ||||
|
NeuroPace Inc
13G/A
Amendment 5
NPCE · 641288105
|
10.5% |
5/15/2025
Event 3/31/2025
|
|||
| OrbiMed Advisors LLC | 10.5% | ||||
| OrbiMed Capital GP VI LLC | 10.5% | ||||
|
InspireMD, Inc.
13G/A
Amendment 2
NSPR · 45779A846
|
7.2% |
5/15/2025
Event 3/31/2025
|
|||
| OrbiMed Advisors LLC | 7.2% | ||||
| OrbiMed Capital GP IX LLC | 6.3% | ||||
|
C4 Therapeutics, Inc.
13G/A
Amendment 1
CCCC · 12529R107
|
6.6% |
5/15/2025
Event 3/31/2025
|
|||
| OrbiMed Advisors LLC | 3.1% | ||||
| OrbiMed Capital LLC | 6.6% | ||||
|
Whitehawk Therapeutics, Inc.
13G
WHWK · 00032Q104
|
8.9% |
5/15/2025
Event 3/31/2025
|
|||
| OrbiMed Advisors LLC | 8.9% | ||||
| OrbiMed Genesis GP LLC | 8.9% | ||||
|
Verastem, Inc.
13G/A
Amendment 3
VSTM · 92337C203
|
5.6% |
5/15/2025
Event 3/31/2025
|
|||
|
Corvus Pharmaceuticals, Inc.
13D/A
Amendment 11
CRVS · 221015100
|
12.2% |
5/14/2025
Event 5/12/2025
|
|||
| Orbimed Advisors LLC | 12.2% | ||||
| Orbimed Capital GP V LLC | 12.2% | ||||
|
Edgewise Therapeutics, Inc.
13D/A
Amendment 4
EWTX · 28036F105
|
14.5% |
5/12/2025
Event 5/9/2025
|
|||
| Orbimed Advisors LLC | 14.5% | ||||
| Orbimed Capital GP VI LLC | 14.1% | ||||
| OrbiMed Genesis GP LLC | 0.4% | ||||
| Orbimed Capital LLC | 0.3% | ||||
|
Corvus Pharmaceuticals, Inc.
13D/A
Amendment 10
CRVS · 221015100
|
13.8% |
5/1/2025
Event 4/29/2025
|
|||
| Orbimed Advisors LLC | 13.8% | ||||
| Orbimed Capital GP V LLC | 13.8% | ||||
|
Passage BIO, Inc.
13D/A
Amendment 6
PASG · 702712100
|
10.7% |
4/25/2025
Event 4/22/2025
|
|||
| Orbimed Advisors LLC | 10.7% | ||||
| Orbimed Capital GP VII LLC | 10.7% | ||||
|
Xtant Medical Holdings, Inc.
13D/A
Amendment 13
XTNT · 98420P308
|
0% |
4/14/2025
Event 4/10/2025
|
|||
| Orbimed Advisors LLC | 0% | ||||
| Orbimed Rof II LLC | 0% | ||||
|
Compass Therapeutics, Inc.
13D/A
Amendment 5
CMPX · 20454B104
|
11.0% |
4/11/2025
Event 4/9/2024
|
|||
| Orbimed Advisors LLC | 11.0% | ||||
| Orbimed Capital GP V LLC | 11.0% | ||||
| OrbiMed Genesis GP LLC | 0% | ||||
| Orbimed Capital LLC | 0% | ||||
|
Disc Medicine, Inc.
13D/A
Amendment 5
IRON · 254604101
|
4.5% |
3/12/2025
Event 3/10/2025
|
|||
| Orbimed Advisors LLC | 4.5% | ||||
| Orbimed Capital GP VI LLC | 1.5% | ||||
| OrbiMed Capital GP VIII LLC | 2.4% | ||||
| OrbiMed Genesis GP LLC | 0.6% | ||||
|
ADC Therapeutics SA
13G
ADCT · H0036K147
|
3.6% |
2/14/2025
Event 12/31/2024
|
|||
| Orbimed Advisors LLC | 2.6% | ||||
| Orbimed Capital LLC | 3.6% | ||||
|
RAPT Therapeutics, Inc.
13G
RAPT · 75382E109
|
9.9% |
2/14/2025
Event 12/31/2024
|
|||
|
Corbus Pharmaceuticals Holdings, Inc.
13G/A
Amendment 1
CRBP · 21833P301
|
5.9% |
2/14/2025
Event 12/31/2024
|
|||
| OrbiMed Advisors LLC | 3.7% | ||||
| OrbiMed Capital LLC | 5.9% | ||||
|
Forte Biosciences, Inc.
13G
FBRX · 34962G208
|
8.0% |
2/14/2025
Event 12/31/2024
|
|||
| Orbimed Advisors LLC | 8.0% | ||||
| Orbimed Capital LLC | 1.4% | ||||
|
Sionna Therapeutics, Inc.
13D
SION · 829401108
|
8.4% |
2/13/2025
Event 2/10/2025
|
|||
| Orbimed Advisors LLC | 8.4% | ||||
| OrbiMed Capital GP VIII LLC | 8.4% | ||||
|
Traws Pharma, Inc.
13D/A
Amendment 2
TRAW · 68232V884
|
19.9% |
1/29/2025
Event 12/31/2024
|
|||
| Orbimed Advisors LLC | 19.9% | ||||
| OrbiMed Capital GP VIII LLC | 19.9% | ||||
|
Passage BIO, Inc.
13D/A
Amendment 5
PASG · 702712100
|
12.0% |
12/26/2024
Event 12/20/2024
|
|||
| Orbimed Advisors LLC | 12.0% | ||||
| Orbimed Capital GP VII LLC | 12.0% | ||||
| Orbimed Capital LLC | 0% | ||||